Abbott India Limited

ABBOTINDIA

INE358A01014

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:49 16/05/2024 pm IST			5-day change	1st Jan Change
26,545 ^INR	+0.42%		+2.31%	+16.16%

10/05	Abbott India's Net Profit Climbs in Fiscal Q4; Shares Up 3%	MT
09/05	Drugmaker Abbott India posts Q4 profit rise on higher sales	RE

Abbott India Limited Announces Appointment of Sabina Ewing as an Additional and Non-Executive Director

June 16, 2021 at 11:28 am IST

Abbott India Limited announced the appointment of Ms Sabina Ewing as an Additional and Non-Executive Director on the Board of the Company effective June 15, 2021 to hold office up to the conclusion of the forthcoming Annual General Meeting of the Company.

Latest news about Abbott India Limited

Abbott India's Net Profit Climbs in Fiscal Q4; Shares Up 3%	10/05	MT
Drugmaker Abbott India posts Q4 profit rise on higher sales	09/05	RE
Abbott India Limited Reports Earnings Results for the Full Year Ended March 31, 2024	09/05	CI
Abbott India Limited Recommends Final Dividend for the Year Ended March 31, 2024, Payable on or After August 13, 2024	09/05	CI
Abbott India Limited Appoints Murari Ranganathan as Commercial Director	12/04	CI
Abbott India's Managing Director Exits	19/03	MT
Abbott India Limited Announces Resignation of Sandeep Reddy - Commercial Director - Women's Health, Metabolics and International Business, with Effect from June 5, 2024	15/03	CI
Abbott India Names Managing Director	13/03	MT
GSK India arm's Q3 profit falls on government price cap	12/02	RE
Abbott India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	15/01	CI
Abbott India Managing Director to Step Down in March 2024	19/12	MT
Abbott India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11	CI
INDIA STOCKS-Indian shares set for muted opening; Delta Corp in focus after tax notice	25/23/25	RE
Abbott India warns of laxatives shortage in tussle with Goa regulator	22/23/22	RE
Goa state warns Abbott India on antacid license suspension	14/23/14	RE
Abbott India Limited Approves Appointment of Sangeeta Shetty as Company Secretary, Effective September 14, 2023	09/23/09	CI
Abbott India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	09/23/09	CI
Abbott India Limited Appoints Ms Richa Tripathi as Associate Director, Effective August 3, 2023	24/23/24	CI
INDIA STOCKS-Indian shares recover from weak start on buying at key levels	22/23/22	RE
Abbott India Limited Approves the Appointment of Sridhar Kadangode as Chief Financial Officer, Effective July 1, 2023	19/23/19	CI
Abbott's India arm posts 9.5% rise in fourth-quarter profit	19/23/19	RE
Abbott India's Net Profit Climbs in Fiscal Q4	19/23/19	MT
Abbott India Limited Approves the Appointment of Mahadeo Karnik as an Additional and Non-Executive Director on the Board, Effective July 1, 2023	19/23/19	CI
Abbott India Limited Reports Earnings Results for the Full Year Ended March 31, 2023	19/23/19	CI
Abbott India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	19/23/19	CI

Chart Abbott India Limited

Duration

Period

More charts

Company Profile

Abbott India Limited is an India-based company that is engaged in the pharmaceuticals business. The Company has a portfolio of offerings in diagnostics, medical devices, nutrition products and branded generic medicines. It provides products and solutions across various therapeutic areas, such as women's health, gastroenterology, central nervous system, metabolic, multi-specialty, and vaccines, among others. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Zolfresh (insomnia), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Creon (pancreatic insufficiency), Cremaffin Plus (Constipation), Pankreoflat (indigestion), Brufen P (fever), Duvadilan (preterm labor), and others. It offers various products under brands, such as Similac, PediaSure, Pedialyte, EleCare, Ensure, Glucerna, and others.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Abbott India Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBOTT INDIA LIMITED	+16.16%	6.73B
ELI LILLY AND COMPANY	+33.22%	709B
NOVO NORDISK A/S	+30.77%	595B
JOHNSON & JOHNSON	-2.09%	367B
MERCK & CO., INC.	+20.12%	334B
ABBVIE INC.	+5.27%	289B
ASTRAZENECA PLC	+14.77%	239B
NOVARTIS AG	+9.13%	211B
ROCHE HOLDING AG	-3.97%	203B
AMGEN INC.	+9.06%	171B

Other Pharmaceuticals